Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (251-260 of 293) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2013
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channelAnne M Noonan, Robin A Eisch, David J Liewehr, et al.
Blood|March 28, 2013
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitorArup R Chakraborty, Robert W Robey, Victoria L Luchenko, et al.
Cancer Research|March 16, 2011
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistanceZhi Shi, Amit K Tiwari, Suneet Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell linesWanqing Liu, Xiaolin Wu, Wei Zhang, et al.
Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.
Biochemical Pharmacology|December 9, 2008
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478Zhi Shi, Amit K Tiwari, Suneet Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.
Seminars in Oncology|November 24, 2019
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamideHarshraj Leuva, Keith Sigel, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2010
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancerRonan J Kelly, Deborah Draper, Clara C Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
The role of breast cancer resistance protein in acute lymphoblastic leukemiaSabine L A Plasschaert, Dorina M van der Kolk, Eveline S J M de Bont, et al.
Pageof 30

Showing results (251-260 of 293) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2013
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channelAnne M Noonan, Robin A Eisch, David J Liewehr, et al.
Blood|March 28, 2013
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitorArup R Chakraborty, Robert W Robey, Victoria L Luchenko, et al.
Cancer Research|March 16, 2011
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistanceZhi Shi, Amit K Tiwari, Suneet Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell linesWanqing Liu, Xiaolin Wu, Wei Zhang, et al.
Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.
Biochemical Pharmacology|December 9, 2008
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478Zhi Shi, Amit K Tiwari, Suneet Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Phase I trial of a new schedule of romidepsin in patients with advanced cancersLaleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, et al.
Seminars in Oncology|November 24, 2019
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamideHarshraj Leuva, Keith Sigel, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2010
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancerRonan J Kelly, Deborah Draper, Clara C Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
The role of breast cancer resistance protein in acute lymphoblastic leukemiaSabine L A Plasschaert, Dorina M van der Kolk, Eveline S J M de Bont, et al.
Pageof 30